Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Citi
Federal Trade Commission
AstraZeneca
Farmers Insurance
Boehringer Ingelheim
Harvard Business School
Fuji
Moodys

Generated: July 21, 2018

DrugPatentWatch Database Preview

Allergan Company Profile

« Back to Dashboard

Summary for Allergan

Drugs and US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes 8,506,987 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-004 Jul 18, 2016 RX Yes No 8,058,291 ➤ Sign Up ➤ Sign Up
Allergan PRED MILD prednisolone acetate SUSPENSION/DROPS;OPHTHALMIC 017100-001 Approved Prior to Jan 1, 1982 RX Yes Yes ➤ Sign Up ➤ Sign Up
Allergan Herbert FLUONID fluocinolone acetonide CREAM;TOPICAL 087156-002 Sep 6, 1984 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 5,212,199 ➤ Sign Up
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 5,227,169 ➤ Sign Up
Allergan Sales Llc DILACOR XR diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 020092-002 May 29, 1992 4,839,177 ➤ Sign Up
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-003 Dec 20, 1996 5,122,383 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-23
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 2008-12-22
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 2011-12-19
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 2006-11-03
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 2008-10-14
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 2014-07-30
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 2005-01-28
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 2010-05-03
➤ Subscribe Capsules 21 mg/10 mg ➤ Subscribe 2016-09-23
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 2011-04-05
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 2011-08-24
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-12-20
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 2008-11-21
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Ophthalmic Solution 0.30% ➤ Subscribe 2007-07-19
➤ Subscribe Capsules 14 mg/10 mg and 28 mg/10 mg ➤ Subscribe 2015-05-18
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 2014-08-12
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 2009-03-02
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2010-12-07
➤ Subscribe Capsules 7 mg/10 mg ➤ Subscribe 2016-09-26
Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for Allergan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,980,290 Transdermal compositions for anticholinergic agents ➤ Sign Up
8,828,446 Method for reducing transplant rejection in the eye and intraocular implants for use therefor ➤ Sign Up
7,732,610 Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents ➤ Sign Up
8,318,070 Ocular implant made by a double extrusion process ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Allergan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00003 Denmark ➤ Sign Up
00C/027 Belgium ➤ Sign Up PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
0568 Netherlands ➤ Sign Up PRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
00454 Netherlands ➤ Sign Up PRODUCT NAME: SILODOSIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/09/607/001-014EU/1/09/608/001-014 2010290129
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
US Department of Justice
Cantor Fitzgerald
Chubb
Accenture
Daiichi Sankyo
McKinsey
Argus Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.